Latest Listings And Ipos News

BetMakers Technology Group reports a strong FY25 trading update, driven by enhancements to its Apollo racing suite and preparations for the GTX wagering platform launch, signaling robust momentum heading into FY26.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Ventia Services Group Limited delivered strong financial results for 2024, highlighted by a 12.8% rise in NPATA and a record 92% contract renewal rate, while reaffirming growth guidance despite ongoing ACCC proceedings.

GQG Partners reported robust financial results for 2024 with significant growth in funds under management and earnings, underscoring its adaptability and alignment with shareholders. The 2025 Annual Meeting confirmed strong investor confidence with near-unanimous director re-election.

AFT Pharmaceuticals reported a 6% increase in revenue to NZ$208 million for the year ending March 2025, but net profit fell 23%, prompting a modest final dividend declaration.

New World Resources Limited has entered a binding agreement for acquisition by Central Asia Metals Plc at a significant premium, valuing the company at approximately A$185 million. The transaction, unanimously recommended by New World’s board, is set to complete by September 2025, subject to shareholder and court approvals.

Aurora Energy Metals has received a further US$550,000 from Eagle Energy Metals, extending the option to acquire the Aurora Uranium Project and underpinning key development milestones.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ assertion of a Material Adverse Change that could derail their acquisition scheme, insisting the deal process continues as planned.

Infomedia Ltd has responded to an ASX price query following a sharp share price decline and increased trading volume, denying any undisclosed material information. The company pointed to the recent closure of Celeste Funds, a known shareholder, as a potential external factor influencing market activity.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

First Au Limited has entered a binding term sheet to progressively acquire full ownership of the Nimba Gold Project in Liberia, backed by a planned A$1 million equity raise to fund exploration. The project’s proximity to a major West African gold mine and promising drill results position FAU for a strategic expansion into a stable, mining-friendly jurisdiction.

Top End Energy has appointed New York-based Amvest Capital to spearhead its U.S. investor engagement and plans an American Depositary Receipt listing by Q3 2025, aiming to open doors to one of the world’s largest energy capital markets.